NCT06702696 Effect of Aronia Berry Consumption on Inflammatory Parameters
| NCT ID | NCT06702696 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Amasya University |
| Condition | COPD (Chronic Obstructive Pulmonary Disease) |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-11-15 |
| Primary Completion | 2025-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-11-15 with a primary completion date of 2025-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will aim to evaluate the effects of consuming freeze-dried aronia berries as an adjunct to medical treatment in patients with chronic obstructive pulmonary disease (COPD), focusing on anti-inflammatory, respiratory, and biochemical parameters. It will be conducted at a research hospital in Istanbul, involving 50 participants aged 50-80 diagnosed with COPD. Participants will be randomly assigned to two groups: the aronia group (AG, n=25) and the placebo group (PG, n=25). The AG will receive 30 g of freeze-dried aronia powder daily, while the PG will receive 30 g of placebo powder, both for a duration of 8 weeks. Baseline demographic data will be collected through face-to-face interviews, while biochemical, respiratory, anthropometric, and body composition parameters will be assessed both before and after the intervention. Dietary intake records will also be collected and analyzed.
Eligibility Criteria
Inclusion Criteria: * Aged 50-80 years * Diagnosed with COPD * Not following a vegetarian or vegan diet * Willing to consume the provided aronia berry (black chokeberry) * Non-smokers * Have signed the informed consent form * Has not undergone endobronchial tube or valve surgery in the last two years. Exclusion Criteria: * Presence of associated chronic inflammatory/rheumatic diseases * Chronic infections that may create a prothrombotic state * Chronic kidney disease (CKD) * Malignancy * Hereditary thrombophilia * Essential thrombocythemia * Diagnosed endocrine disorders * Malabsorption disorders * Allergy to any food or berry fruits * Smoking * Participants who did not sign the informed consent form
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06702696 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying COPD (Chronic Obstructive Pulmonary Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06702696 currently recruiting?
Yes, NCT06702696 is actively recruiting participants. Contact the research team at buse-sarikaya@hotmail.com for enrollment information.
Where is the NCT06702696 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06702696 clinical trial?
NCT06702696 is sponsored by Amasya University. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.